What’s the current market cap for Enhabit, Inc. stock?

Enhabit, Inc. (EHAB) has a market cap of $707m as of June 16, 2026.

What is the P/E ratio for Enhabit, Inc. stock?

The price to earnings (P/E) ratio for Enhabit, Inc. (EHAB) stock is 0 as of June 16, 2026.

Does Enhabit, Inc. stock pay dividends?

No, Enhabit, Inc. (EHAB) stock does not pay dividends to its shareholders as of June 16, 2026.

When is the next Enhabit, Inc. dividend payment date?

Enhabit, Inc. (EHAB) stock does not pay dividends to its shareholders.

What is the beta indicator for Enhabit, Inc.?

Enhabit, Inc. (EHAB) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Enhabit, Inc. stock | $EHAB Share Price

13:30

15:10

16:45

18:25

20:00

About Enhabit, Inc.

Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.

Ticker

$EHAB

Sector

Health

Primary listing

NYSE

Employees

10,800

Headquarters

Dallas, United States

Website

www.ehab.com

Enhabit, Inc. Metrics

BasicAdvanced

$707m

-$0.06

0.96

What the Analysts think about Enhabit, Inc.

Majority rating from 8 analysts.

Hold

Bulls say / Bears say

Enhabit’s Q4 2025 net service revenue rose 4.7% YoY to $270.4 M, driven by a 3.2% increase in home health and 10.0% growth in hospice, underscoring strong demand across its care segments. (Nasdaq)

The $13.80 per share all-cash acquisition by Kinderhook Industries represents a 24.4% premium to Enhabit’s February 20, 2026 closing stock price, affirming robust valuation and strategic interest. (Investing.com)

Following the final CMS Medicare rule cutting rates by 1.3% versus the proposed 6.4%, Enhabit expects a reduced EBITDA headwind of $6-8 M for 2026, prompting UBS and TD Cowen to upgrade their ratings to Buy. (Investing.com)

In Q4 2025, Medicare admissions declined 4.0% to 22,196 and revenue per episode fell 2.3% to $2,931, highlighting softness in Enhabit’s core Medicare payor segment. (Nasdaq)

Enhabit’s leverage profile tightened with a $315 M term loan and $160 M revolving credit facility under its amended credit agreement, accompanied by a net interest expense of $7.4 M in Q4 2025, raising refinancing and liquidity risks. (TradingView)

Multiple shareholder lawsuits and investigations by Brodsky & Smith and Kaskela law firms challenge the equity sale’s fairness, alleging fiduciary breaches in the $13.80 per share buyout, potentially increasing legal costs and procedural delays. (TradingView)

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EHAB

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

Enhabit’s Q4 2025 net service revenue rose 4.7% YoY to $270.4 M, driven by a 3.2% increase in home health and 10.0% growth in hospice, underscoring strong demand across its care segments. (Nasdaq)

In Q4 2025, Medicare admissions declined 4.0% to 22,196 and revenue per episode fell 2.3% to $2,931, highlighting softness in Enhabit’s core Medicare payor segment. (Nasdaq)

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.